Dr. Reddy’s Laboratories Limited is the name of a company that produces pharmaceutical goods (NYSE: RDY). Zacks Research raised their earnings projection for Dr. Reddy’s Laboratories’ FY2023, published in a study made available on Wednesday, February 8. Zacks Research analyst E.
Bagri has revised his earlier forecast of the company’s profits per share upward, moving it from $2.90 to $3.22.
This upward revision brings the total to $3.22.
According to the most recent estimates, Dr. Reddy’s Laboratories will make $3.31 per share in profit over the entire year.
According to the projections made by Zacks Research, Dr. Reddy’s Laboratories will bring in revenue equivalent to $0.59 per share during the fourth quarter of 2023.
According to projections made by Zacks Research, the earnings per share for the first quarter of 2024 would be $0.69, the earnings per share for the second quarter of 2024 would be $0.77, the earnings per share for the third quarter of 2024 would be $0.78, the earnings per share for the full year of 2024 would be $3.14, the earnings per share for the first quarter of 2025 would be $0.85, the earnings per share for the second quarter of 2025 would be $0.88, and the earnings per share for the third quarter of 2025 would be
When trading started on Friday, the share price of Dr. Reddy’s Laboratories was $54.37.
The share price is $9.05 billion, the price-to-earnings ratio is 20.14, and the price-to-earnings growth ratio is 0.59.
The stock’s beta is 0.48 and it has a price-to-earnings-growth ratio of 0.59.
The price-to-earnings growth ratio is a method for determining how rapidly earnings are expanding compared to the market.
The financial ratios are as follows:
The debt-to-equity ratio is at 0.
The current ratio is 2.30.
The quick ratio is at 1.72.
The quick ratio is at 1.
The company’s moving average price over the previous 50 days is $53.24, and the moving average price over the previous 200 days is $53.25. Over the last 52 weeks, the share price of Dr. Reddy’s Laboratories has ranged from as low as $47.88 to as high as $58.28.
The stock these equity analysts have been following has also been the subject of research reports published by other equity analysts. Credit Suisse Group moved Dr. Reddy’s Laboratories from the rating of “neutral” to the rating of “underperform” in a research note published on November 14.
Barclays gave the company an “overweight” rating in a research note published on October 31.
Additionally, the firm increased its price objective for Dr. Reddy’s Laboratories from $66,000 to $67,000. On Monday, October 31, the rating that StockNews.com had previously given for Dr. Reddy’s Laboratories was raised to “strong buy” from its previous designation. JPMorgan Chase & Co announced their intention to start covering the shares of Dr. Reddy’s Laboratories in a research note released on January 30.
They rated the stock as “underweight,” the lowest possible rating.
There have been three different recommendations regarding the stock’s direction:
Two research experts suggested selling the stock.
One research analyst suggested buying the stock.
Another strongly suggested buying the stock.
The stock is currently rated as having a consensus recommendation of “Hold,” and an average price target of $67.50 has been set for the stock, according to data sourced from Bloomberg.com.
In addition, the price target for the stock has been set at $67.50.
In recent times, it has become common practice for several hedge funds to change the sector strategies they employ.
During the last three months of 2018, Dimensional Fund Advisors L.P.
Increased its stake in Dr. Reddy’s Laboratories by purchasing an additional 4.20 percent of the company’s shares. Following the completion of the period, Dimensional Fund Advisors L.P.
Acquired an additional 34,849 shares of the company’s stock, bringing the total number of shares it currently owns to 871,786.
The value of these shares places a $45,120,000 price tag on the company’s stock.
During the fourth and final quarter, Augustine Asset Management INC increased the amount of Dr. Reddy’s Laboratories stock held by 116.0%.
Augustine Asset Management INC now has a total of 51,153 shares of the company’s stock, valued at a combined total of $2,647,000, after purchasing an additional 27,468 shares during the period in question.
This brings the total number of shares owned by the company to 51,153.
The purchase of a new investment in Dr. Reddy’s Laboratories cost Thrivent Financial for Lutherans approximately $733,000.
This purchase was made during the fourth quarter.
LPL Financial LLC increased its holdings in Dr. Reddy’s Laboratories by approximately $477,000 during the fourth quarter by making additional investments in the company.
During the final three months of the year, Robeco Institutional Asset Management B.V.
Added approximately $45,709,000 worth of Dr. Reddy’s Laboratories shares to its existing portfolio of investments.
To the tune of 9.81% of the outstanding shares, hedge funds, and other institutional investors are the owners.
The company known as Dr. Reddy’s Laboratories Ltd has been manufacturing and distributing a wide range of pharmaceutical goods.
It conducts its business under various divisions, the most prominent of which are Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others.
The Global Generics segment includes the production and marketing of finished pharmaceutical products that are ready for patient consumption.
These products may be marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations; either way, they are considered ready for patient consumption.
These pharmaceutical products may be marketed under a brand name or as finished dosages bearing a generic name.
Leave a comment